Table 1.
Demographics and baseline characteristics of patients with COVID-19
| All patients (n=93) | Survivors (n=68) | Nonsurvivors (n=25) | p value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 51.0±17.5 | 43.7±13.1 | 69.0±10.5 | <0.011 |
| Sex | ||||
| Female | 52(56%) | 42(62%) | 10(40%) | 0.0982 |
| Male | 41(44%) | 26(38%) | 15(60%) | |
| Signs and symptoms | ||||
| Fever | 89(96%) | 66(97%) | 25(100%) | 1.02 |
| Dry cough | 66(71%) | 59(87%) | 8(32%) | <0.012 |
| Fatigue | 63(68%) | 45(66%) | 20(80%) | 0.382 |
| Expectoration | 29(31%) | 17(25%) | 12(48%) | <0.052 |
| Diarrhea | 16(17%) | 12(18%) | 4(16%) | 1.03 |
| Anorexia | 37(40%) | 21(31%) | 17(68%) | <0.012 |
| Myalgia | 34(37%) | 26(38%) | 9(36%) | 1.02 |
| Dyspnea | 32(34%) | 12(18%) | 20(80%) | <0.012 |
| Comorbidities | 32(34%) | 12(18%) | 16(64%) | <0.012 |
| Diabetes | 11(12%) | 6(9%) | 5(20%) | 0.1582 |
| Hypertension | 5(5%) | 0 | 5(20%) | |
| Cardiovascular disease | 4(4%) | 0 | 4(16%) | |
| Chronic obstructive pulmonary disease | 8(9%) | 6(9%) | 2(8%) | 1.03 |
| Malignancy | 4(4%) | 3(4%) | 1(4%) | 1.03 |
| Duration (days) | 21.6±6.8 | 21.8±5.8 | 21.2±8.9 | 0.7351 |
| Treatments | ||||
| Antibiotics | 71(76%) | 68(100%) | 3(12%) | <0.00013 |
| Antiviral treatment | 71(76%) | 68(100%) | 3(12%) | <0.00013 |
| Corticosteroids | 21(23%) | 0 | 21(84%) | <0.00013 |
| Intravenous immunoglobin | 89(96%) | 68(100%) | 21(84%) | 0.0043 |
| High-flow nasal cannula oxygen therapy | 24(26%) | 1(1.5%) | 23(92%) | <0.00013 |
| Non-invasive mechanical ventilation | 11(12%) | 0 | 11(44%) | <0.00013 |
| Invasive mechanical ventilation | 5(5.4%) | 0 | 5(20%) | <0.00013 |
Note: Data are n (%) or mean ± SD, unless otherwise specified. 1Mann-Whitney U test; 2Chi-square test; 3Fisher's exact test owing to expected count less than 5 for at least one cell.